<DOC>
	<DOCNO>NCT00603512</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety , 3 month , 4 dose regimen CP-690,550 , combine methotrexate , treatment active rheumatoid arthritis .</brief_summary>
	<brief_title>Comparison Of 4 CP-690,550 Doses Vs . Placebo , Each Combined With Methotrexate , For The Treatment Of Rheumatoid Arthritis Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Active rheumatoid arthritis Inadequate response stably dose methotrexate Current therapy DMARD biologic methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phase II MTX add-on study Japan</keyword>
</DOC>